Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Borner

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
The Journal of Biological Chemistry|August 15, 2003
Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patternsMario P Tschan, Kimberlee M Fischer, Vivian S Fung, et al.
Proteomics|July 18, 2009
Novel functional profiling approach combining reverse phase protein microarrays and human 3-D ex vivo tissue cultures: expression of apoptosis-related proteins in human colon cancerFarzaneh Pirnia, Michael Pawlak, Gerhard G Thallinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer ResearchM Borner, M Bacchi, A Goldhirsch, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)A D Roth, R Herrmann, R Morant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trialA D Roth, R Maibach, N Fazio, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group studyF Duffaud, M Borner, P Chollet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 daysC Sessa, C Minoia, A Ronchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)M M Borner, M Castiglione, M Bacchi, et al.
British Journal of Cancer|March 10, 1999
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancerM M Borner, P Brousset, B Pfanner-Meyer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group reportB Coudert, A Anthoney, W Fiedler, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
The Journal of Biological Chemistry|August 15, 2003
Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patternsMario P Tschan, Kimberlee M Fischer, Vivian S Fung, et al.
Proteomics|July 18, 2009
Novel functional profiling approach combining reverse phase protein microarrays and human 3-D ex vivo tissue cultures: expression of apoptosis-related proteins in human colon cancerFarzaneh Pirnia, Michael Pawlak, Gerhard G Thallinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer ResearchM Borner, M Bacchi, A Goldhirsch, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)A D Roth, R Herrmann, R Morant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trialA D Roth, R Maibach, N Fazio, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group studyF Duffaud, M Borner, P Chollet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 daysC Sessa, C Minoia, A Ronchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)M M Borner, M Castiglione, M Bacchi, et al.
British Journal of Cancer|March 10, 1999
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancerM M Borner, P Brousset, B Pfanner-Meyer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group reportB Coudert, A Anthoney, W Fiedler, et al.
Pageof 8